BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31451417)

  • 1. Targeted Radioimmunotherapy and Theranostics with Alpha Emitters.
    Pandit-Taskar N
    J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S41-S44. PubMed ID: 31451417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha radioimmunotherapy using
    Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
    Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
    Cheal SM; Fung EK; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Wittrup KD; Cheung NV; Larson SM
    J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretargeted radioimmunotherapy with α-particle emitting radionuclides.
    Lindegren S; Frost SH
    Curr Radiopharm; 2011 Jul; 4(3):248-60. PubMed ID: 22201711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted alpha therapy: part I.
    Elgqvist J
    Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein targeting constructs in alpha therapy.
    Olafsen T; Elgqvist J; Wu AM
    Curr Radiopharm; 2011 Jul; 4(3):197-213. PubMed ID: 22201709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The promise of targeted {alpha}-particle therapy.
    Mulford DA; Scheinberg DA; Jurcic JG
    J Nucl Med; 2005 Jan; 46 Suppl 1():199S-204S. PubMed ID: 15653670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of different classes of radionuclides for potential use in radioimmunotherapy.
    Karagiannis TC
    Hell J Nucl Med; 2007; 10(2):82-8. PubMed ID: 17684582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters.
    Waldmann T
    Leuk Lymphoma; 2003; 44 Suppl 3():S107-13. PubMed ID: 15202533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy with alpha-particle emitting radionuclides.
    Zalutsky MR; Pozzi OR
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
    Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
    Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Radionuclide Theranostic Pretargeting.
    Keinänen O; Brennan JM; Membreno R; Fung K; Gangangari K; Dayts EJ; Williams CJ; Zeglis BM
    Mol Pharm; 2019 Oct; 16(10):4416-4421. PubMed ID: 31483993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides.
    Sgouros G; Hobbs R; Josefsson A
    Curr Radiopharm; 2018; 11(3):209-214. PubMed ID: 29697036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer radioimmunotherapy with alpha-emitting nuclides.
    Couturier O; Supiot S; Degraef-Mougin M; Faivre-Chauvet A; Carlier T; Chatal JF; Davodeau F; Cherel M
    Eur J Nucl Med Mol Imaging; 2005 May; 32(5):601-14. PubMed ID: 15841373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics.
    Huclier-Markai S; Alliot C; Varmenot N; Cutler CS; Barbet J
    Curr Top Med Chem; 2012; 12(23):2642-54. PubMed ID: 23339760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy with α-particle-emitting radionuclides.
    Seidl C
    Immunotherapy; 2014; 6(4):431-58. PubMed ID: 24815783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
    Yao Z; Zhang M; Garmestani K; Axworthy DB; Mallett RW; Fritzberg AR; Theodore LJ; Plascjak PS; Eckelman WC; Waldmann TA; Pastan I; Paik CH; Brechbiel MW; Carrasquillo JA
    Clin Cancer Res; 2004 May; 10(9):3137-46. PubMed ID: 15131055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretargeting: A Path Forward for Radioimmunotherapy.
    Cheal SM; Chung SK; Vaughn BA; Cheung NV; Larson SM
    J Nucl Med; 2022 Sep; 63(9):1302-1315. PubMed ID: 36215514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy using alpha emitters.
    Vaidyanathan G; Zalutsky MR
    Phys Med Biol; 1996 Oct; 41(10):1915-31. PubMed ID: 8912371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.